You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, November 2015
|
| DOI | 10.1186/s40425-015-0093-x |
| Pubmed ID | |
| Authors |
Amabel CL Tan, Anne Goubier, Holbrook E. Kohrt |
| Abstract |
Despite the progress that has been made in other forms of cancer therapy, Provenge® (Sipuleucel-T) is the only FDA-approved vaccine for the treatment of cancer. To understand the current landscape of therapeutic oncology vaccines we performed a quantitative analysis of phase 2 and phase 3 therapeutic cancer vaccine trials. We highlight shifts in trends for the vaccine platforms examined, common adjuvant use, target indications, antibody or treatment combinations between past and recent trials as well as discuss the relationship between these trends and ratio between the number of phase 3: phase 2 for different vaccine platforms. Despite the poor success rate in vaccine approvals, registration of phase 3 trials between 2010 and 2014 were stable indicating continued investment and efforts towards development of immunotherapeutic vaccines. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 92 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 1% |
| Unknown | 91 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 20 | 22% |
| Student > Ph. D. Student | 13 | 14% |
| Student > Bachelor | 10 | 11% |
| Student > Master | 6 | 7% |
| Other | 5 | 5% |
| Other | 15 | 16% |
| Unknown | 23 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 18% |
| Agricultural and Biological Sciences | 12 | 13% |
| Immunology and Microbiology | 11 | 12% |
| Biochemistry, Genetics and Molecular Biology | 5 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 5% |
| Other | 16 | 17% |
| Unknown | 26 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 November 2015.
All research outputs
#17,285,668
of 25,373,627 outputs
Outputs from Journal for Immunotherapy of Cancer
#2,887
of 3,421 outputs
Outputs of similar age
#237,385
of 392,667 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#78
of 98 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,421 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one is in the 11th percentile – i.e., 11% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 392,667 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 98 others from the same source and published within six weeks on either side of this one. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.